Lisinopril, >=98% (HPLC)

Application

Lisinopril has been used to study the antifibrotic effect in duchenne muscular dystrophy mice. It has been used to study the changes in renal-structure and -function in TGR(mRen2)27 (transgenic rat harboring the murine Ren-2 gene) rats upon long term darbepoetin ? treatment.

Biochem/physiol Actions

Angiotensin converting enzyme (ACE) inhibitor.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

100, 250 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3591662 Lisinopril, >=98% (HPLC) white 100 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2
£586.39 (exc VAT) per 100MG
-
+
3591663 Lisinopril, >=98% (HPLC) white 100 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2
£1,026.54 (exc VAT) per 250MG
-
+